Assertio Therapeutics, a commercial pharmaceutical company (NASDAQ:), has had a more than 40% decline in shares year-to-date. The stock recovered momentum last week after Assertio Therapeutics reported higher-than-expected earnings. Can the stock continue its rally despite unfavorable analysts’ expectations? You can read the rest of this article. Assertio Therapeutics, Inc., which is a Newark, Calif.-based commercial pharmaceutical company, offers pain, inflammation, and neurology treatments. ASRT stock has fallen 29.7% in price over the past year and 40.8% year-to-date to close yesterday’s trading session at $1.55. The stock has also fallen 40.8% in the last six months due to conspiracies against the company.

Bausch Health Cos Inc., ASRT and Lupin Pharmaceuticals were accused of conspiring to buy Bausch’s diabetes drug Glumetza to stop generic competition by a patent settlement. Glumetza Antitrust Litigation was settled by the company for $7.0million. This amount includes a $3.85 Million class settlement, subject to approval from the court.

After the company announced its third quarter earnings, the stock price increased 37.2%. This was higher than the consensus estimate. ASRT’s net income came in at $3.74 million, reflecting a 135.5% increase year-over-year, while its EPS increased 122.9% year-over-year to $0.08 versus the negative $0.04 consensus estimate. But the company’s total revenues declined 26.3% from its prior-year quarter to $25.47 million.

Continue reading on StockNews